[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337802-105":59,"doc-detail-337802-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","synergistic-immunoregulation-harnessing-circrnas-and-pirnas-to-amplify-pd-1pd-l1-inhibition-therapy-review","Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy - Review","","The utilization of PD-1/PD-L1 inhibitors marks a significant advancement in cancer therapy. However, the efficacy of monotherapy is still disappointing in a substantial subset of patients, necessitating the exploration of combinational strategies. Emerging from the promising results of the KEYNOTE-942 trial, RNA-based therapies, particularly circRNAs and piRNAs, have distinguished themselves as innovative sensitizers to immune checkpoint inhibitors (ICIs). These non-coding RNAs regulate PD-L1 expression and bolster anti-cancer immunity. The review synthesizes mechanisms and therapeutic prospects for combining circRNAs and piRNAs to enhance PD-1/PD-L1 inhibition, supported by transformative mRNA vaccine advances.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/synergistic-immunoregulation-harnessing-circrnas-and-pirnas-to-amplify-pd-1pd-l1-inhibition-therapy-review/337802/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/synergistic-immunoregulation-harnessing-circrnas-and-pirnas-to-amplify-pd-1pd-l1-inhibition-therapy-review/337802.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is combination therapy needed with PD-1/PD-L1 inhibitors?","Question",{"text":112,"@type":113},"Monotherapy benefits are limited for a substantial subset of patients, so combinational strategies are explored to improve sustained clinical outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do circRNAs and piRNAs function as immune-checkpoint sensitizers?",{"text":117,"@type":113},"They are non-coding RNAs that regulate PD-L1 expression and modulate immune responses, thereby enhancing the activity of PD-1/PD-L1 inhibition.",{"name":119,"@type":110,"acceptedAnswer":120},"What trial and evidence are highlighted in the review?",{"text":121,"@type":113},"The abstract emphasizes promising results from the KEYNOTE-942 trial and discusses how RNA-based approaches may act as sensitizers for immune checkpoint inhibitors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337802,1790647774,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","International Journal of Nanomedicine Dovepress  \nopen access to scientific and medical research  \n Open Access Full Text Article REVIEW  \nSynergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy  \nRui Han 1 , 2 , Xiwu Rao 3 , Huiling Zhou4 , Lingeng Lu 5–7  \n1Department of Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, People’s Republic of China; 2Department of Chinese Medicine, Naval Medical University, Shanghai, People’s Republic of China; 3Department of Oncology, The First Hospital Affiliated to Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People’s Republic of China; 4Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, People’s Republic of China; 5Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, New Haven, CT, USA; 6School of Medicine, Center for Biomedical Data Science, Yale University, New Haven, CT, USA; 7Yale Cancer Center, Yale University, New Haven, CT, USA  \nCorrespondence: Rui Han, Department of Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, People’s Republic of China, Email [dianxiqiao@foxmail.com](dianxiqiao@foxmail.com)  \n\n| Abstract: The utilization of PD-1/PD-L1 inhibitors marks a significant advancement in cancer therapy. However, the efficacy of monotherapy is still disappointing in a substantial subset of patients, necessitating the exploration of combinational strategies. Emerging from the promising results of the KEYNOTE-942 trial, RNA-based therapies, particularly circRNAs and piRNAs, have distinguished themselves as innovative sensitizers to immune checkpoint inhibitors (ICIs) . These non-coding RNAs, notable for their stability and specificity, were once underrecognized but are now known for their crucial roles in regulating PD-L1 expression and bolstering anti-cancer immunity. Our manuscript offers a comprehensive analysis of selected circRNAs and piRNAs, elucidating their immunomodulatory effects and mechanisms, thus underscoring their potential as ICIs enhancers. In conjunction with the recent Nobel Prize-awarded advancements in mRNA vaccine technology, our review highlights the transformative implications of these findings for cancer treatment. We also discuss the prospects of circRNAs and piRNAs in future therapeutic applications and research. This study pioneers the synergistic application of circRNAs and piRNAs as novel sensitizers to augment PD-1/PD-L1 inhibition therapy, demonstrating their unique roles in regulating PD-L1 expression and modulating immune responses. Our findings offera groundbreaking approach for enhancing the efficacy of cancer immunotherapy, opening new avenues for treatment strategies. This abstract aims to encapsulate the essence of our research and the burgeoning role of these non-coding RNAs in enhancing PD-1/ PD-L1 inhibition therapy, encouraging further investigation into this promising field.\u003Cbr>Keywords: CircRNA, piwi-RNA, immunotherapy, PD-1/PD-L1 blockade, immunotherapy sensitizer, combination therapy |\n| --- |\n| Introduction\u003Cbr>According to GLOBOCAN, there were 19.3 million.1, new cancer cases and 10.0 million cancer-related deaths worldwide in 2020.2 In 2019, the World Health Organization (WHO) estimated that cancer ranks as the primary or secondary cause of death before the age of 70 in 112 out of 183 countries.2 As a formidable ailment, the available therapeutic options for cancer remain limited.3 The advent of immune checkpoint inhibitor therapy, including PD-1 (Programmed Cell Death Protein 1) and PD-L1 (Programmed Death-Ligand 1) inhibitors, has revolutionized cancer treatment and, to some extent, improved clinical outcomes for cancer patients. However, a significant portion of cancer patients still struggle to achieve sustained and optimal clinical benefits.3–5\u003Cbr>Therefore, the concept of incor","cbCair3Gf8d89FNd","https://ap.wps.com/l/cbCair3Gf8d89FNd","pdf",8773143,32,"English","# Introduction\n## Rationale for sensitizers in PD-1/PD-L1 therapy\n\n# Background and therapeutic context\n## Immune checkpoint inhibitor outcomes and limitations\n## Rationale for combining with RNA-based sensitizers\n\n# Review focus","[{\"question\":\"Why is combination therapy needed with PD-1/PD-L1 inhibitors?\",\"answer\":\"Monotherapy benefits are limited for a substantial subset of patients, so combinational strategies are explored to improve sustained clinical outcomes.\"},{\"question\":\"How do circRNAs and piRNAs function as immune-checkpoint sensitizers?\",\"answer\":\"They are non-coding RNAs that regulate PD-L1 expression and modulate immune responses, thereby enhancing the activity of PD-1/PD-L1 inhibition.\"},{\"question\":\"What trial and evidence are highlighted in the review?\",\"answer\":\"The abstract emphasizes promising results from the KEYNOTE-942 trial and discusses how RNA-based approaches may act as sensitizers for immune checkpoint inhibitors.\"}]","Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy - Review | PDF",1790020701,81,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14c1f51c32f659b19a3db52a73bcc7b7.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00de9224ff98e77f7ecdabb8d3dcf6c6.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ecc11668d72266d5d55318db006a98b.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81b4b2f6212d1cd0f58172743f7701d7.webp",980,1268]